ID: ALA3321887

Max Phase: Preclinical

Molecular Formula: C15H22N2O3

Molecular Weight: 278.35

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  COc1cc(CN2CCCC2)ccc1OC(=O)N(C)C

Standard InChI:  InChI=1S/C15H22N2O3/c1-16(2)15(18)20-13-7-6-12(10-14(13)19-3)11-17-8-4-5-9-17/h6-7,10H,4-5,8-9,11H2,1-3H3

Standard InChI Key:  MWJIAHNJNJSKPU-UHFFFAOYSA-N

Associated Targets(non-human)

Acetylcholinesterase 2577 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Butyrylcholinesterase 745 Activities

Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 278.35Molecular Weight (Monoisotopic): 278.1630AlogP: 2.35#Rotatable Bonds: 4
Polar Surface Area: 42.01Molecular Species: NEUTRALHBA: 4HBD: 0
#RO5 Violations: 0HBA (Lipinski): 5HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 8.34CX LogP: 1.88CX LogD: 0.90
Aromatic Rings: 1Heavy Atoms: 20QED Weighted: 0.85Np Likeness Score: -1.07

References

1. Li Y, Peng P, Tang L, Hu Y, Hu Y, Sheng R..  (2014)  Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer's disease therapy.,  22  (17): [PMID:25082512] [10.1016/j.bmc.2014.07.009]

Source